Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology Brothers
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Lung Cancer More Likely Than AIDS-Related Causes to Kill HIV Patients

September 22, 2017
By Leah Lawrence
Article

People living with HIV who adhere to antiretroviral therapy but still smoke cigarettes are substantially more likely to die from lung cancer than from AIDS-related causes, according to the results of a new study.

People living with HIV who adhere to antiretroviral therapy (ART) but still smoke cigarettes are substantially more likely to die from lung cancer than from AIDS-related causes, according to the results of a study published in JAMA Internal Medicine.

“Using a microsimulation model, we found that ART-adherent people living with HIV in the United States who smoke cigarettes are 6 to 13 times more likely to die from lung cancer than from AIDS-related causes,” wrote Krishna P. Reddy, MD, of Massachusetts General Hospital and Harvard Medical School, and colleagues. “Even when accounting for reported rates of ART nonadherence and loss to follow-up, we found that nearly 10% of people living with HIV initially linked to HIV care (including both smokers and nonsmokers) are expected to die from lung cancer if smoking habits do not change.”

According to the study, more than 40% of people living with HIV in the United States smoke cigarettes, which is more than twice the prevalence among the general population.

The researchers conducted this study to calculate the cumulative lung cancer mortality rate by age 80 and total expected lung cancer deaths among people living with HIV in the United States. To do that, they created a microsimulation model of HIV and applied standard demographic data and recent HIV/AIDS epidemiology statistics with specific details on smoking exposure, combining smoking status (current, former, or never) and intensity (heavy, moderate, or light).

Among 40-year-old men with HIV, the estimated cumulative lung cancer mortality rates were 28.9% for heavy smokers, 23.0% for moderate smokers, and 18.8% for light smokers. In comparison, for those who quit smoking at age 40, the cumulative lung cancer mortality rates were 7.9%, 6.1%, and 4.3%, respectively. Among those who had never smoked, the estimated cumulative lung cancer mortality rate was 1.6%.

Mortality rates were similar among women. The cumulative lung cancer mortality rate for a 40-year-old woman with HIV who was a heavy smoker was 27.8%; for moderate and light smokers, the rates were 20.9% and 16.6%. For former smokers, mortality rates decreased to 7.5%, 5.2%, and 3.7%, respectively. For never smokers, it was 1.2%.

“For 40-year-old ART-adherent men who were current moderate smokers, the combined cumulative mortality from lung cancer and other non–AIDS-related causes-both of which were increased by smoking-was approximately 35 times that from AIDS-related causes (79.9% vs 2.3%),” the researchers wrote. For women in this category, it was approximately 27 times higher (66.6% vs 2.5%).

When the researchers applied model projections to the approximately 644,200 people living with HIV, age 20 to 64 years, in the United States, they found that 9.3% are expected to die from lung cancer if smoking habits do not change.

“Clinicians caring for people living with HIV should offer guideline-based behavioral and pharmacologic treatments for tobacco use,” the researchers wrote. “Lung cancer is now a leading cause of death among people living with HIV, but smoking cessation can greatly reduce the risk. Lung cancer prevention, especially through smoking cessation, should be a priority in the comprehensive care of people living with HIV.”

The researchers noted that the study was limited in part because of its design as a model-based study.

Recent Videos
In a CancerNetwork® YouTube video, Cornelia Tischmacher, a mother of twins from Germany, outlined her receipt of double lung transplantation.
Ongoing ctDNA analysis may elucidate outcomes associated with divarasib plus migoprotafib for those with KRAS G12C–positive NSCLC.
The FirstLook liquid biopsy, when used as an adjunct to low-dose CT, may help to address the unmet need of low lung cancer screening utilization.
An 80% sensitivity for lung cancer was observed with the liquid biopsy, with high sensitivity observed for early-stage disease, as well.
Related Content
Advertisement

Benmelstobart With/Without Anlotinib Is Effective Consolidation Therapy in NSCLC

Benmelstobart With/Without Anlotinib Is Effective Consolidation Therapy in NSCLC

Jordyn Sava
June 3rd 2025
Article

Benmelstobart-based regimens provide clinically meaningful PFS benefits as consolidation therapy for unresectable stage III non–small cell lung cancer.


Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.

Exploring the Value of Preoperative CAPTEM in Atypical Lung NETs

Georgios Evangelou, MD, MSc
September 16th 2024
Podcast

Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.


3 Things You Should Know About the Multimodal Treatment of SCLC

3 Things You Should Know About the Multimodal Treatment of SCLC

Lauren Averett Byers, MD;Percy Lee, MD, FASTRO;Erminia Massarelli, MD, PhD, MS
May 19th 2025
Article

Here are 3 things you should know about the multimodal treatment of patients with SCLC.


Rian M. Hasson Charles, MD, MPH, FACS, discusses advances in equitable lung cancer screening and her experiences as a woman in thoracic oncology.

Achieving Health Equity in Lung Cancer Surgery

Rian M. Hasson Charles, MD, MPH, FACS
April 1st 2024
Podcast

Rian M. Hasson Charles, MD, MPH, FACS, discusses advances in equitable lung cancer screening and her experiences as a woman in thoracic oncology.


“[O]ur findings show that large-scale lung cancer screening is both feasible and effective, and provide a framework for successful delivery of a population-based national program,” according to the study authors.

Low-Dose CT Screening for Lung Cancer Shows Large-Scale Efficacy

Russ Conroy
April 29th 2025
Article

Study data show a small number of individuals with a lung cancer diagnosis within 12 months of a negative baseline screening result.


Chemoimmunotherapy-Enhanced Survival vs Chemotherapy Alone in ES-SCLC

Chemoimmunotherapy-Enhanced Survival vs Chemotherapy Alone in ES-SCLC

Tim Cortese
April 27th 2025
Article

Patients with ES-SCLC who received immunotherapy plus chemotherapy experienced a median OS of 14.9 months vs 11.9 months with chemotherapy alone.

Related Content
Advertisement

Benmelstobart With/Without Anlotinib Is Effective Consolidation Therapy in NSCLC

Benmelstobart With/Without Anlotinib Is Effective Consolidation Therapy in NSCLC

Jordyn Sava
June 3rd 2025
Article

Benmelstobart-based regimens provide clinically meaningful PFS benefits as consolidation therapy for unresectable stage III non–small cell lung cancer.


Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.

Exploring the Value of Preoperative CAPTEM in Atypical Lung NETs

Georgios Evangelou, MD, MSc
September 16th 2024
Podcast

Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.


3 Things You Should Know About the Multimodal Treatment of SCLC

3 Things You Should Know About the Multimodal Treatment of SCLC

Lauren Averett Byers, MD;Percy Lee, MD, FASTRO;Erminia Massarelli, MD, PhD, MS
May 19th 2025
Article

Here are 3 things you should know about the multimodal treatment of patients with SCLC.


Rian M. Hasson Charles, MD, MPH, FACS, discusses advances in equitable lung cancer screening and her experiences as a woman in thoracic oncology.

Achieving Health Equity in Lung Cancer Surgery

Rian M. Hasson Charles, MD, MPH, FACS
April 1st 2024
Podcast

Rian M. Hasson Charles, MD, MPH, FACS, discusses advances in equitable lung cancer screening and her experiences as a woman in thoracic oncology.


“[O]ur findings show that large-scale lung cancer screening is both feasible and effective, and provide a framework for successful delivery of a population-based national program,” according to the study authors.

Low-Dose CT Screening for Lung Cancer Shows Large-Scale Efficacy

Russ Conroy
April 29th 2025
Article

Study data show a small number of individuals with a lung cancer diagnosis within 12 months of a negative baseline screening result.


Chemoimmunotherapy-Enhanced Survival vs Chemotherapy Alone in ES-SCLC

Chemoimmunotherapy-Enhanced Survival vs Chemotherapy Alone in ES-SCLC

Tim Cortese
April 27th 2025
Article

Patients with ES-SCLC who received immunotherapy plus chemotherapy experienced a median OS of 14.9 months vs 11.9 months with chemotherapy alone.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.